Premium
Association of MCP‐1 and CCR2 polymorphisms with the risk of late acute rejection after renal transplantation in Korean patients
Author(s) -
Kang S. W.,
Park S. J.,
Kim Y. W.,
Kim Y. H.,
Sohn H. S.,
Yoon Y. C.,
Joo H.,
Jeong K. H.,
Lee S. H.,
Lee T. W.,
Ihm C. G.
Publication year - 2008
Publication title -
international journal of immunogenetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.41
H-Index - 47
eISSN - 1744-313X
pISSN - 1744-3121
DOI - 10.1111/j.1744-313x.2007.00725.x
Subject(s) - genotype , ccr2 , transplantation , gastroenterology , medicine , immunology , restriction fragment length polymorphism , receptor , chemokine , chemokine receptor , biology , gene , genetics
Summary Among the factors modulating transplant rejection, chemokines and their respective receptors deserve special attention. Increased expression of monocyte chemoattractant protein‐1 (MCP‐1) and its corresponding receptor (chemokine receptor‐2, CCR2) has been implicated in renal transplant rejection. To determine the impact of the MCP‐1‐2518G and CCR2‐64I genotypes on renal allograft function, 167 Korean patients who underwent transplantation over a 25‐year period were evaluated. Genomic DNA was genotyped using polymerase chain reaction followed by restriction fragment length polymorphism analysis. Fifty‐five (32.9%) patients were homozygous for the MCP‐1‐2518G polymorphism. Nine (5.4%) patients were homozygous for the CCR2‐64I polymorphism. None of the investigated polymorphism showed a significant shift in long‐term allograft survival. However, a significant increase was noted for the risk of late acute rejection in recipients who were homozygous for the MCP‐1‐2518G polymorphism (OR, 2.600; 95% CI, 1.125–6.012; P = 0.022). There was also an association between the MCP‐1‐2518G/G genotype and the number of late acute rejection episodes ( P = 0.024). Although there was no difference in the incidence of rejection among recipients stratified by the CCR2‐V64I genotype, recipients with the CCR2‐V64I GG genotype in combination with the MCP‐1‐2518G/G genotype had a significantly higher risk of acute or late acute rejection among the receptor‐ligand combinations ( P = 0.006, P = 0.008, respectively). The MCP‐1 variant may be a marker for risk of late acute rejection in Korean patients.